Recommendations by ASAIO on selection and treatment of patients with respiratory and circulatory failure associated with COVID-19 using artificial pulmonary and/or cardiac support.
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
The expert panel structured their recommendations to answer 8 pertinent questions related to tracheostomy procedures in patients with COVID-19-related respiratory failure.
Dysanapsis may be associated with a higher incidence of COPD in older adults.
An expert panel released a set of 22 guidelines for the prevention, detection, and treatment of venous thromboembolism.
The FDA has granted Orphan Drug Designation to Tacrolimus Inhalation Powder (TFF Pharmaceuticals) for prophylaxis of lung allograft rejection.
COVID-19 was diagnosed in <10% of out-of-hospital cardiac arrests in the Seattle area.
Acromegaly is associated with an increased risk for mortality from vascular and respiratory disease, but not malignant disease.
Starting pulmonary rehabilitation within 3 months of hospital discharge significantly reduced the risk of 1-year mortality in Medicare beneficiaries hospitalized for COPD.
Lung ultrasound B-lines can depict modifications in the lung parenchyma of patients with systemic sclerosis and may be an independent predictor of additional pulmonary deterioration in individuals with the disease.
The COVID-19 pandemic has posited a significant risk to healthcare workers, particularly to those who perform bronchoscopy, among other open airway procedures.
Patients with sarcoidosis have an increased risk of in-hospital mortality if they present with heart failure, atrial fibrillation, or pulmonary hypertension.
High plasma omega-3 polyunsaturated fatty acid levels have been shown to be associated with a slower progression of percent emphysema.
While the incidence of minor bleeding events during endobronchial ultrasound with transbronchial needle aspiration is higher in patients who receive antiplatelet medications, these medications are still warranted in select patients.
An RV/LV ratio >1.0 was not associated with fewer favorable outcomes in patients with symptomatic acute pulmonary embolism who were otherwise considered otherwise low risk.